Background: Ramelteon is a selective MT1/MT2 melatonin receptor agonist approved by the
US Food and Drug Administration for insomnia treatment. Objective: The aim of this post hoc …

Objective: Ramelteon is an MT1/MT2 melatonin receptor agonist indicated for the treatment
of insomnia characterized by difficulty with sleep onset. In previous clinical studies …

BACKGROUND AND PURPOSE: To evaluate the efficacy, safety, and dose response of
Ramelteon, a novel highly selective MT1/MT2 receptor agonist, in patients with chronic …

OBJECTIVE: To evaluate the efficacy and safety of ramelteon, a highly selective MT1/MT2
melatonin receptor agonist, for the treatment of transient insomnia in adults. METHODS: In a …

Objective: To evaluate efficacy and safety of ramelteon (MT1/MT2-receptor agonist) in
subjects with chronic primary insomnia. Methods: Randomized, multicenter, double-blind …

Ramelteon (Rozerem™) is the first melatonin receptor agonist to be approved for the
treatment of insomnia; it is not classified as a controlled substance. In patients with chronic …

BACKGROUND:: Insomnia is a common sleep disorder with a significant potential for
deleterious effects on activities of daily living, productivity, and overall quality of life …

BACKGROUND AND PURPOSE: To assess the efficacy and safety of ramelteon, a selective
MT1/MT2 receptor agonist, for chronic insomnia treatment. PATIENTS AND METHODS …

Objective: To assess the efficacy and safety of ramelteon, a selective melatonin MT1/MT2-
receptor agonist, for insomnia treatment in older adults. Methods: In a randomized, 9‑week …

Abstract Study Objectives: Long-duration (≥ 6 months) polysomnographic studies of
insomnia medications are lacking. This study evaluated the long-term efficacy of ramelteon …